Controversies in dose-escalation for locally advanced non-small cell lung cancer and the role of proton beam therapy

We appreciate the insightful commentary by Drs. Choi and Simone regarding the phase II study of concurrent chemotherapy and dose-escalated proton beam therapy (PBT) for locally advanced non-resected non-small cell lung cancer (NSCLC) (1). We wish to add several discussion points that are in concord with the aforementioned piece